trimethoprim--sulfamethoxazole-drug-combination has been researched along with Venous-Thrombosis* in 2 studies
2 other study(ies) available for trimethoprim--sulfamethoxazole-drug-combination and Venous-Thrombosis
| Article | Year |
|---|---|
Isolated eosinophilic mesenteric vasculitis with extensive thrombosis and splenic infarction in a 13-year-old boy.
There are no generally accepted diagnostic criteria for primary systemic vasculitis, and the application of classification as diagnostic criteria is not feasible and may even be misleading. We report a case of a 13-year-old boy with acute abdomen who was found to have isolated eosinophilic mesenteric vasculitis with extensive thrombosis and splenic infarction. All serological tests were negative, including antineutrophil cytoplasmic antibody. The vasculitis had been successfully controlled with surgical intervention, steroid, and cyclophosphamide therapy. This may be an atypical presentation of Churg-Strauss syndrome. Topics: Adolescent; Anti-Infective Agents; Chemotherapy, Adjuvant; Cyclophosphamide; Eosinophilia; Humans; Immunosuppressive Agents; Jejunum; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Prednisone; Splenic Infarction; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vasculitis; Venous Thrombosis | 2007 |
Stenotrophomonas maltophilia infection of the central venous catheter and lysis of an old thrombosis in a post-bone marrow transplantation child: implications in the fibrinolytic process.
In this report, we describe an 11-y-old girl who developed jugular venous thrombosis after allogeneic bone marrow transplantation for lymphoma and then experienced dissolution of the thrombosis following catheter-related Stenothrophomonas maltophilia bactearemia. The lysis of the old thrombosis around the central venous catheter suggested a local fibrinolytic activity of S. maltophilia. The global fibrinolytic capacity (GFC) was also tested in vitro by using S. maltophilia cultures obtained from the present patient; GFC of the patient was compared to that of another isolate of S. maltophilia, other bacteria (S. pyogenes and E. coli), and control plasma. The fibrinolytic capasity of S. maltophilia was significantly higher than that of the control plasma (p<0.05) and almost equal to that of S. pyogenes (p>0.05). Thus, if a potent local fibrinolytic activity of S. maltophilia is evident, the use of the fibrinolytic enzyme of S. maltophilia as a thrombolytic agent may be a useful therapeutic adjunct in the future. Further studies are needed to comfirm the results obtained in the present study. Topics: Amikacin; Bacteriolysis; Bone Marrow Transplantation; Catheterization, Central Venous; Child; Ciprofloxacin; Drug Therapy, Combination; Female; Fibrinolysin; Gram-Negative Bacterial Infections; Humans; Jugular Veins; Stenotrophomonas maltophilia; Transplantation, Homologous; Trimethoprim, Sulfamethoxazole Drug Combination; Venous Thrombosis | 2007 |